Comparative Therapy Evaluation of Intravitreal Bevacizumab and Triamcinolone Acetonide on Peritent Diffue Diabetic Macular Edema Original Reearch Article

Purpoe To compare the effect of an intravitreal injection of bevacizumab, an anti-vacular endothelial growth factor (VEGF) antibody, with that of triamcinolone acetonide, a corticoteroid for reduction of diabetic macular edema (DME). Deign Propective, comparative interventional cae erie. Method Twenty-eight eye of 14 patient with bilateral DME participated in thi tudy. In each patient, one eye received an intravitreal injection of 4 mg triamcinolone acetonide and the other eye received 1.25 mg bevacizumab. The clinical coure of bet-corrected viual acuity (VA) with a logarithm of the minimum angle of reolution chart and averaged foveal thickne uing optical coherence tomography wa monitored for up to 24 week after the injection. Reult Before the injection, foveal thickne and VA were 522.3 ± 91.3 μm and 0.64 ± 0.28 μm in the triamcinolone-injected eye, and 527.6 ± 78.8 μm and 0.61 ± 0.18 μm in the bevacizumab-injected eye, repectively; there wa no ignificant difference between the eye. One week after the injection, both eye howed ignificant regreion of macular edema. The triamcinolone-injected eye (342.6 ± 85.5 μm and 0.33 ± 0.21 μm) howed ignificantly better reult than the bevacizumab-injected eye (397.6 ± 103.0 μm and 0.37 ± 0.17 μm). However, both eye howed the recurrence of macular edema with time, even at 24 week. Triamcinolone (410.4 ± 82.4 μm and 0.47 ± 0.25 μm) kept better reult than bevacizumab (501.6 ± 92.5 μm and 0.61 ± 0.17 μm). Concluion With the generally ued concentration, intravitreal injection of triamcinolone acetonide howed better reult in reducing DME and in the improvement of VA than that of bevacizumab, uggeting that the pathogenei of DME i not only attributable to VEGF-dependency, but i alo attributable to other mechanim uppreed by corticoteroid.